The U.S. Food and Drug Administration on Thursday authorized Merck & Co’s antiviral pill for COVID-19, after giving the go-ahead to a similar treatment from Pfizer Inc. a day earlier.
Merck’s drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30 per cent in a clinical trial of high-risk individuals early in the course of the illness.
The agency authorized the oral drug for the treatment of mild-to-moderate COVID-19 in adults who are at risk for severe disease, and for whom alternative COVID-19 treatments are not accessible or clinically appropriate.
The U.S. government has a contract to buy as many as five million courses of the drug for $700 per course.
The drug is not authorized for use in patients younger than 18 because molnupiravir may affect bone and cartilage growth, the FDA said in a statement.
More Stories
Global measles cases nearly doubled in one year, researchers say
How to make conversations with aging parents a little less awkward | CBC Radio
N.S. mom calls for better ultrasound access after private clinic reveals twins | Globalnews.ca